Skip to main content
HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
Home
Table of Contents
Test, Evaluate, Monitor
Treatment-Naive Patients
Treatment-Experienced Patients
Unique & Key Populations
About the Guidance
Home
»
Table of Contents
Introduction
Methods
»
Methods Table 1
Methods Table 2
Methods Table 3 Abbreviations
References
Test, Evaluate, Monitor
»
Testing and Linkage to Care
When and in Whom
Cost, Reimbursement, and Cost-Effectiveness
Monitoring
Incomplete Adherence
HCV Resistance
Treatment-Naive
»
Simplified: No Cirrhosis
Simplified: Comp. Cirrhosis
Decompensated Cirrhosis
Genotype 1
»
GT1a: No Cirrhosis
GT1a: Compensated
GT1b: No Cirrhosis
GT1b: Compensated
Genotype 2
»
GT2 : No Cirrhosis
GT2 : Compensated
Genotype 3
»
GT3 : No Cirrhosis
GT3 : Compensated
Genotype 4
»
GT4 : No Cirrhosis
GT4 : Compensated
Genotype 5 or 6
Treatment-Experienced
»
SOF-Based and ELB/GRZ Treatment Failures
G/P Treatment Failures
Multiple DAA Treatment Failures
Decompensated Cirrhosis
Unique & Key Populations
»
HIV/HCV Coinfection
Decompensated Cirrhosis
Post Liver Transplant
Organs from HCV-Viremic Donors
Renal Impairment
Kidney Transplant
Acute Infection
HCV in Pregnancy
HCV in Children
PWID, MSM & Corrections
»
People Who Inject Drugs
Men Who Have Sex With Men
Correctional Settings
About
»
Announcements
Organizations
Panel
Disclosures
Process
Citing and Permissions
Survey
Website Policies
Contact
Menu
Home »
Table of Contents
Introduction
Methods »
Methods Table 1
Methods Table 2
Methods Table 3 Abbreviations
References
Test, Evaluate, Monitor »
Testing and Linkage to Care
When and in Whom
Cost, Reimbursement, and Cost-Effectiveness
Monitoring
Incomplete Adherence
HCV Resistance
Treatment-Naive »
Simplified: No Cirrhosis
Simplified: Comp. Cirrhosis
Decompensated Cirrhosis
Genotype 1 »
GT1a: No Cirrhosis
GT1a: Compensated
GT1b: No Cirrhosis
GT1b: Compensated
Genotype 2 »
GT2 : No Cirrhosis
GT2 : Compensated
Genotype 3 »
GT3 : No Cirrhosis
GT3 : Compensated
Genotype 4 »
GT4 : No Cirrhosis
GT4 : Compensated
Genotype 5 or 6
Treatment-Experienced »
SOF-Based and ELB/GRZ Treatment Failures
G/P Treatment Failures
Multiple DAA Treatment Failures
Decompensated Cirrhosis
Unique & Key Populations »
HIV/HCV Coinfection
Decompensated Cirrhosis
Post Liver Transplant
Organs from HCV-Viremic Donors
Renal Impairment
Kidney Transplant
Acute Infection
HCV in Pregnancy
HCV in Children
PWID, MSM & Corrections »
People Who Inject Drugs
Men Who Have Sex With Men
Correctional Settings
About »
Announcements
Organizations
Panel
Disclosures
Process
Citing and Permissions
Survey
Website Policies
Contact
You are here
Home
›
References
›
Foster 2015a
Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection.
Foster GR, Afdhal NH, Roberts SK
.
Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection.
N Engl J Med. 2015;373(27):2608-2617.
Publication Type:
Journal Article
Authors:
Graham R. Foster
;
N H Afdhal
;
S K Roberts
Source:
N Engl J Med., Volume 373, Issue 27, p.2608-2617 (2015)
Top
